Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB

• Published in: PloS one Vol. 9; no. 8; p. e105346
• Main Authors: Raizada, Neeraj, Sachdeva, Kuldeep Singh, Nair, Sreenivas Achuthan, Kulsange, Shubhangi, Gupta, Radhey Shayam, Thakur, Rahul, Parmar, Malik, Gray, Christen, Ramachandran, Ranjani, Vadera, Bhavin, Ekka, Shobha, Dhawan, Shikha, Babre, Ameet, Ghedia, Mayank, Alavadi, Umesh, Dewan, Puneet, Khetrapal, Mini, Khanna, Ashwini, Boehme, Catharina, Paramsivan, Chinnambedu Nainarappan
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 20-08-2014; Public Library of Science (PLoS)
• Subjects: Adolescent; Antibiotics, Antitubercular - pharmacology; Child; Child, Preschool; Children; Cross-Sectional Studies; Diagnosis; Diagnostic systems; Drug resistance; Drug Resistance, Bacterial; Health care facilities; Health facilities; Humans; Infant; Infant, Newborn; Medical diagnosis; Medicine and Health Sciences; Microscopy; Molecular Diagnostic Techniques - standards; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - genetics; Pediatrics; Population studies; Public health; Quality Improvement; Rifampin; Rifampin - pharmacology; Smear; Sputum; Sputum - microbiology; Statistical analysis; Tuberculosis; Tuberculosis, Pulmonary - diagnosis; Tuberculosis, Pulmonary - microbiology; Switzerland; India
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0105346

Diagnosis of pulmonary tuberculosis (PTB) in children is challenging due to difficulties in obtaining good quality sputum specimens as well as the paucibacillary nature of disease. Globally a large proportion of pediatric tuberculosis (TB) cases are diagnosed based only on clinical findings. Xpert MTB/RIF, a highly sensitive and specific rapid tool, offers a promising solution in addressing these challenges. This study presents the results from pediatric groups taking part in a large demonstration study wherein Xpert MTB/RIF testing replaced smear microscopy for all presumptive PTB cases in public health facilities across India.
The study covered a population of 8.8 million across 18 programmatic sub-district level tuberculosis units (TU), with one Xpert MTB/RIF platform established at each study TU. Pediatric presumptive PTB cases (both TB and Drug Resistant TB (DR-TB)) accessing any public health facilities in study area were prospectively enrolled and tested on Xpert MTB/RIF following a standardized diagnostic algorithm.
4,600 pediatric presumptive pulmonary TB cases were enrolled. 590 (12.8%, CI 11.8-13.8) pediatric PTB were diagnosed. Overall 10.4% (CI 9.5-11.2) of presumptive PTB cases had positive results by Xpert MTB/RIF, compared with 4.8% (CI 4.2-5.4) who had smear-positive results. Upfront Xpert MTB/RIF testing of presumptive PTB and presumptive DR-TB cases resulted in diagnosis of 79 and 12 rifampicin resistance cases, respectively. Positive predictive value (PPV) for rifampicin resistance detection was high (98%, CI 90.1-99.9), with no statistically significant variation with respect to past history of treatment.
Upfront access to Xpert MTB/RIF testing in pediatric presumptive PTB cases was associated with a two-fold increase in bacteriologically-confirmed PTB, and increased detection of rifampicin-resistant TB cases under routine operational conditions across India. These results suggest that routine Xpert MTB/RIF testing is a promising solution to present-day challenges in the diagnosis of PTB in pediatric patients.